Skip to main content
. 2018 Oct 6;219(6):898–907. doi: 10.1093/infdis/jiy592

Table 2.

Predictors of Progression to Clinically Significant CMV Infection by Cox Regression Analysis

Variable Univariate Analysis Multivariate Analysis
Crude HR (95% CI) P Value Adjusted HR (95% CI) P Value
Age 0.99 (0.96–1.01) .32
Sex .12 a
 Male Reference
 Female 1.74 (0.86–3.54)
Race .89
 White Reference
 African American 0.67 (0.09–4.97)
 Hispanic 0.64 (0.15–2.70)
 Other 0.81 (0.31–2.13)
Type of cancer .25
 Leukemia Reference
 Lymphoma 0.32 (0.08–1.35)
 Other 0.66 (0.23–1.90)
Type of transplant .003 a
 Matched related donor Reference
 Matched unrelated donor 4.75 (1.43–15.73)
 Autologous 24.83 (3.90–158.15)
Steroids useb 5.85 (2.61–13.11) <.0001 4.87 (2.12–11.19) .002
GVHD 1.39 (0.65–2.96) .39
HCT donor status .009 a
 CMV− Reference
 CMV+ 0.35 (0.16–0.77)
Time from HCT to enrollment, d 0.99 (0.97–1.02) .47
CMV-CMIb <.0001 <.0001
 High Reference Reference
 Low 9.68 (3.49–26.80) 9.02 (3.19–25.51)

High CMV-CMI was defined as a pp65 of >100 per 250000 cells and/or an IE1 SPC of >50 per 250000 cells. Low CMV-CMI was defined as a pp65 SPC of ≤100 per 250000 cells and an IE1 of ≤50 SPC per 250000 cells. CMV load was excluded from the multivariate Cox regression analysis as it was highly related to the ELISPOT CMV assay results.

Abbreviations: CI, confidence interval; CMV, cytomegalovirus; CMV-CMI, cytomegalovirus cell mediated immunity; GVHD, graft versus host disease; HCT, hematopoietic cell transplant; HR, hazard ratio; SPC, spot count.

aVariable was entered into the initial multivariate Cox regression model based on the P value of its univariate analysis (≤.20) and later removed from the final Cox regression model through the backward elimination procedure.

bSteroid use and CMV-CMI level (low/high) were time-dependent variables in the Cox regression analysis as they changed over time during the study period.